TRANSFORM美国临床试验:INTUITY快速部署主动脉瓣系统性能评价
TRANSFORM为前瞻性、非随机、多中心、单臂试验,纳入839例严重主动脉瓣狭窄患者行INTUITY快速部署主动脉瓣置换,技术成功率95%,30天全因死亡率0.8%,1年血流动力学表现良好,但永久起搏器植入率为11.9%,高于欧洲试验,需进一步研究。
要点
- INTUITY快速部署瓣技术成功率95%,30天全因死亡率0.8%。
- 全胸骨切开者主动脉阻断与体外循环时间短于STS数据库对照(P<.001)。
- 孤立性主动脉瓣置换者永久起搏器植入率11.9%,高于欧洲试验。
核心结论
- INTUITY快速部署主动脉瓣置换在北美试验中表现有效,可能相对缩短主动脉阻断与体外循环时间,血流动力学性能优异。
- 观察到的永久起搏器植入率略高于欧洲试验,需进一步研究。
研究设计与样本
- TRANSFORM为前瞻性、非随机、多中心(n=29)、单臂试验,注册号NCT01700439。
- 2012至2015年间共839例严重主动脉瓣狭窄患者接受INTUITY快速部署主动脉瓣置换。
- 平均年龄73.5±8.3岁,59%采用全胸骨切开,41%采用微创切口。
- 主要终点与有效性终点于1年时评价。
主要发现
- 技术成功率95%。
- 30天全因死亡率0.8%,瓣膜取出0.1%,血栓栓塞3.5%,大出血1.3%。
- 孤立性主动脉瓣置换者永久起搏器植入率11.9%。
- 1年平均有效瓣口面积1.7 cm2,平均跨瓣压差10.3 mm Hg。
- 1年中度与重度瓣周漏分别为1.2%与0.4%。
关键数值与推荐
- 孤立性快速部署主动脉瓣置换全胸骨切开者平均主动脉阻断时间49.3±26.9分钟,体外循环时间69.2±34.7分钟。
- 孤立性快速部署主动脉瓣置换微创切口者平均主动脉阻断时间63.1±25.4分钟,体外循环时间84.6±33.5分钟。
- 上述时间优于STS数据库对照:全胸骨切开为76.3分钟与104.2分钟,微创切口为82.9分钟与111.4分钟(P<.001)。
临床怎么用
- 对于严重主动脉瓣狭窄需行主动脉瓣置换者,INTUITY快速部署系统可作为缩短阻断与体外循环时间的选择。
- 术后需关注永久起搏器植入风险,尤其孤立性主动脉瓣置换患者起搏器植入率达11.9%。
- 术后随访应评估瓣周漏与血流动力学,1年中重度瓣周漏分别为1.2%与0.4%。
局限性
- 试验为单臂、非随机设计,缺乏同期随机对照。
- 永久起搏器植入率高于欧洲试验,其原因需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) trial (NCT01700439) evaluated the performance of the INTUITY rapid deployment aortic valve replacement (RDAVR) system in patients with severe aortic stenosis. METHODS: TRANSFORM was a prospective, nonrandomized, multicenter (n = 29), single-arm trial. INTUITY is comprised of a cloth-covered balloon-expandable frame attached to a Carpentier-Edwards PERIMOUNT Magna Ease aortic valve. Primary and effectiveness endpoints were evaluated at 1 year. RESULTS: Between 2012 and 2015, 839 patients underwent RDAVR. Mean age was 73.5 ± 8.3 years. Full sternotomy (FS) was used in 59% and minimally invasive surgical incisions in 41%. Technical success rate was 95%. For isolated RDAVR, mean crossclamp and cardiopulmonary bypass times for FS were 49.3 ± 26.9 minutes and 69.2 ± 34.7 minutes, respectively, and for minimally invasive surgical 63.1 ± 25.4 minutes and 84.6 ± 33.5 minutes, respectively. These times were favorable compared with Society of Thoracic Surgeons database comparators for FS: 76.3 minutes and 104.2 minutes, respectively, and for minimally invasive surgical, 82.9 minutes and 111.4 minutes, respectively (P < .001). At 30 days, all-cause mortality was 0.8%; valve explant, 0.1%; thromboembolism, 3.5%; and major bleeding, 1.3%. In patients with isolated aortic valve replacement, the rate of permanent pacemaker implantation was 11.9%. At 1 year, mean effective orifice area was 1.7 cm2; mean gradient, 10.3 mm Hg; and moderate and severe paravalvular leak, 1.2% and 0.4%, respectively. CONCLUSIONS: INTUITY RDAVR performed effectively in this North American trial. It may lead to a relative reduction in aortic crossclamp time and cardiopulmonary bypass time and has excellent hemodynamic performance. Pacemaker implantation rate observed was somewhat greater than European trials and requires further investigation.
引用
- Barnhart GR, Accola KD, Grossi EA, et al. TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial: Performance of a rapid deployment aortic valve. J Thorac Cardiovasc Surg. 2016. PMID: 27817951. doi:10.1016/j.jtcvs.2016.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。